NK Cell Infusion for Patients With Acute Myeloid Leukemia

Inclusion Criteria: 1. AML patients receiving standard NCCN induction and consolidation chemotherapy; 2. Age\> = 18 years old; 3. Relapsed and refractory AML: continued non-remission after induction and consolidation chemotherapy with NCCN standard protocol, or relapse after remission, or continued MRD positive; 4. MDS-RAEB, MDS-AML, MPD-AML; 5. ECOG≤3; 6. No serious organ dysfunction within 2 weeks before treatment: 1. Heart: no arrhythmia and LVEF≥50% and no pericardial effusion; 2. Liver: liver function \<2 times the upper limit of ALT and \<1.5 times the upper limit of total bilirubin, no active hepatitis; 3. Kidney: serum creatinine \<1.5 mg / dl; or if serum creatinine exceeds the upper limit, serum creatinine clearance should be CrCl\> 50 ml / min; 4. indoor fingertip blood oxygen saturation ≧ 92%; 7. Expected survival time ≥ 3 months; 8. The interval between re-induction therapy and NK cell therapy is at least 2 weeks, and the toxic and side effects of all induction remission treatments have disappeared; if the patient is receiving non-invasive chemotherapy, such as hydroxyurea, low-dose cytarabine, before receiving this program Should be discontinued before; 9. All patients and donors are willing to join this clinical trial and sign informed consent. Exclusion Criteria: 1. Combined with a history of other malignant tumors \<5 years (except cured skin basal cell carcinoma, cured cervical carcinoma in situ and gastrointestinal tumors confirmed to be cured by endoscopic mucosal resection); 2. Have received bone marrow or organ transplant; 3. Those who are allergic to the biological agents used in this treatment; 4. active infection; 5. Those who received other cell treatments such as DLI, CMV-CTL, EBV-CTL; 6. HBV carriers; 7. Patients with extramedullary recurrence; 8. Chest radiographic examination to determine patients with pulmonary inflammation; 9. Researchers do not consider it appropriate to participate in this trial.